BioMarin
Develops rare-disease medicines across enzyme therapies, metabolic disorders, and skeletal conditions.
$64.67
After-hours close+0.02 (+0.02%)
At close$64.65(−0.98%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 107.12%Insiders 0.53%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 193.28M · Float 192.09M · 99.4% free float
Institutions13F, as of Jun 30, 2026
586 holders · 207.05M shares · 88 new positions · 294 increased · 194 reduced · 84 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 20.45M | 10.58% | +626.9K | Aug 7, 2026 |
| Dodge & Cox | 14.84M | 7.68% | +283.2K | Aug 13, 2026 |
| Primecap Management Co/CA/ | 14.19M | 7.34% | −3.8K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 8.74M | 4.52% | +100.5K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 8.65M | 4.47% | +350.2K | Aug 13, 2026 |
| Norges Bank | 8.21M | 4.25% | +8.21Mnew | Aug 12, 2026 |
| State Street Corp | 7.80M | 4.04% | +505.9K | Aug 7, 2026 |
| Viking Global Investors LP | 7.62M | 3.94% | +554.5K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 9.10% | 17.56M | 13G | Jan 21, 2026 ↗ |
| Primecap Management Co/CA/ | 8.24% | 15.80M | 13G | Aug 14, 2025 ↗ |
| Vanguard Capital Management | 5.25% | 10.11M | 13G | Apr 29, 2026 ↗ |
| Viking Global Investors LPincl. Viking Long Fund Master Ltd., Viking Global Equities Master Ltd. +10 more | 5.10% | 9.75M | 13G | Sep 30, 2024 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Alexander Hardy | director, officer: Chief Executive Officer | 214.6K | 0.11% | Mar 19, 2026 |
| Richard A. Meier | director | 127.4K | 0.07% | May 22, 2025 |
| Brian Mueller | officer: EVP, Chief Financial Officer | 123.3K | 0.06% | Mar 19, 2026 |
| Charles Greg Guyer | officer: EVP, Chief Technical Officer | 84.1K | 0.04% | Mar 19, 2026 |
| George Eric Davis | officer: EVP, Chief Legal Officer | 78.6K | 0.04% | Mar 19, 2026 |
| Gregory R. Friberg | officer: EVP, Chief R&D Officer | 51.8K | 0.03% | May 11, 2026 |
| Robert J. Hombach | director | 49.4K | 0.03% | Jun 4, 2026 |
| Willard H. Dere | director | 46.4K | 0.02% | Jun 4, 2026 |
| Cristin Hubbard | officer: EVP, Chief Commercial Officer | 42.5K | 0.02% | May 21, 2026 |
| Elizabeth M. Anderson | director | 41.9K | 0.02% | Jun 4, 2026 |
25 people have not refiled in the last 18 months (2.23M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 7, 2026 | Gregory R. Fribergofficer: EVP, Chief R&D Officer | Sale | 3,281 | $53.85 | 51,818 |
| Mar 11, 2026 | Charles Greg Guyerofficer: EVP, Chief Technical Officer | Sale | 16,486 | $60.46 | 79,953 |
| Feb 26, 2026 | George Eric Davisofficer: EVP, Chief Legal Officer | Sale | 26,061 | $61.36 | 72,453 |
| Feb 26, 2026 | Gregory R. Fribergofficer: EVP, Chief R&D Officer | Sale | 6,326 | $60.38 | 37,578 |
CongressHouse and Senate disclosures
Not reported.